BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment

Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older...

December 20, 2024 | News

Everest Medicines’ VELSIPITY® Prescribed in Mainland China, Pioneering New Ulcerative Colitis Treatment under Hong Kong-Macau Connect

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

December 18, 2024 | News

Everest Medicines Announces First Prescription of VELSIPITY® for Ulcerative Colitis in Macau, Marking a Key Milestone in Asia

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

December 13, 2024 | News

Hong Kong’s Viva Biotech Expands Global Footprint with Strategic Boston Branch Launch

Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in drug re...

December 12, 2024 | News

Alamar Biosciences Expands to APAC with ARGO™ HT System Installation at HKCeND

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in th...

December 09, 2024 | News

Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Approved for Pediatric Use in Hong Kong

Pfizer announced that the Hong Kong Department of Health (DoH) has approved its 20-valent Pneumococcal Conjugate Vaccine (PCV20) for active immunization in...

December 04, 2024 | News

Everest Medicines’ New Drug Application for VELSIPITY® (etrasimod) Accepted in Hong Kong for Ulcerative Colitis

Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeut...

December 03, 2024 | News

Merck and Abbisko Report Phase III Success for Pimicotinib in TGCT Treatment

Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0% for pimicotinib versus 3.2% for placebo (p<0.0001) ...

November 27, 2024 | News

Akeso's Penpulimab and Anlotinib Combo Accepted by NMPA for First-Line Advanced Liver Cancer Treatment

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accep...

November 25, 2024 | News

Novotech and Biostar Announce Long-Term Partnership to Accelerate Oncology Clinical Development

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advan...

November 13, 2024 | News

Illumina and PHASE Scientific Forge Strategic Partnership to Drive Genomic Innovation in Greater Bay Area

llumina Hong Kong LIMITED (Illumina), a global leader in DNA sequencing and array-based technologies, and PHASE Scientific International Limited (PHASE), a...

November 11, 2024 | News

Ascletis' ASC47 Shows Promise in Phase I Trial with Once-Monthly Dosing and Superior Fat Reduction in Obesity Treatment

Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed...

November 08, 2024 | News

Hong Kong's Akeso Biopharma Advances Immunotherapy in Biliary Tract Cancer with First Patient Enrolled in Phase III Study of Ivonescimab

Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, c...

November 01, 2024 | News

Hong Kong’s Akeso Biopharma Enrolls First Patient in Pioneering Phase III Trial for Advanced Head and Neck Cancer Therapy

Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (A...

October 31, 2024 | News

Stay Connected